Viewing Study NCT02281357


Ignite Creation Date: 2025-12-24 @ 6:57 PM
Ignite Modification Date: 2026-02-21 @ 6:01 AM
Study NCT ID: NCT02281357
Status: COMPLETED
Last Update Posted: 2019-03-15
First Post: 2014-10-30
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Asthma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Asthma View
None Reactive Airways View
None Repiratory Tract Disease View
None Obstructive Lung Disease View
None Lung Diseases View